ANOKION
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
ANOKION
Social Links:
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2010-01-01
Address:
Ecublens, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.anokion.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
112.61 M USD
Technology used in webpage:
Euro U.S. Server Location Cogent Communications
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-09-11 | Kanyos Bio | Kanyos Bio acquired by Anokion | N/A |
Investors List
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Venture Round - Anokion
Versant Ventures
Versant Ventures investment in Series B - Anokion
Novo Ventures
Novo Ventures investment in Series B - Anokion
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Anokion
Celgene
Celgene investment in Series B - Anokion
André J. Mueller
André J. Mueller investment in Series A - Anokion
Novo Ventures
Novo Ventures investment in Series A - Anokion
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Anokion
Versant Ventures
Versant Ventures investment in Series A - Anokion
Harry Welten
Harry Welten investment in Series A - Anokion
Official Site Inspections
http://www.anokion.com Semrush global rank: 3.15 M Semrush visits lastest month: 4.77 K
- Host name: cloudproxy10011.sucuri.net
- IP address: 192.124.249.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Anokion"
Anokion - Crunchbase Company Profile & Funding
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the …See details»
Overview - Anokion
Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary …See details»
Anokion Company Profile 2024: Valuation, Funding & Investors
Anokion General Information Description. Developer of antigen-specific immunotherapy designed to offer services for immune tolerance. The company's immunotherapy focuses on both …See details»
Anokion Overview | SignalHire Company Profile
Anokion is a private company that has been in the industry for 13 years. The company currently specializes in the Biotechnology, Biotechnology areas. ... Organization Website: anokion.com : …See details»
Overview - Anokion
Investors. Anokion is well-funded by Versant Ventures, Novartis Venture Fund, Novo Ventures, as well as private Switzerland-based personal investors.See details»
Anokion - Work in biotech
Anokion is a clinical-stage biotech company that aims to improve autoimmune disease treatment, which typically involves systemic immunosuppression, leaving patients vulnerable to viruses, …See details»
Anokion - Funding, Financials, Valuation & Investors - Crunchbase
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance. Search Crunchbase. Start Free Trial . ... Which types of acquisition …See details»
Anokion SA - BioAlps
Avenue de Sécheron 15 1202 Geneva, Switzerland T +41 22 545 12 91. c/o BIOPÔLE SA Secteur Esplanade / Bâtiment Serine Route de la Corniche 8 1066 Epalinges, SwitzerlandSee details»
Anokion Company Profile - Office Locations, Competitors ... - Craft
Anokion has 5 employees across 2 locations and $77.61 m in total funding,. See insights on Anokion including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Anokion - Company Profile & Staff Directory - ContactOut
Anokion | 2,301 followers on LinkedIn. Restoring normal IMMUNE TOLERANCE to treat autoimmune disease | Anokion SA is a Swiss biotechnology company that aims to make a …See details»
Anokion - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Anokion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Anokion has 6 current employee profiles, …See details»
Anokion SA - Drug pipelines, Patents, Clinical trials - Synapse
Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of …See details»
Anokion Announces $35 Million Equity Investment from Pfizer
Oct 18, 2022 About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune …See details»
Anokion Announces Positive Symptom Data from its Phase 2 Trial ...
Jan 8, 2025 CAMBRIDGE, Mass. & LAUSANNE, Switzerland, January 08, 2025--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring …See details»
Anokion Announces the Early Completion of Enrollment in the …
Dec 19, 2024 Cambridge, Mass. and Lausanne, Switzerland, December 19, 2024 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring …See details»
Anokion Announces Positive Symptom Data from its Phase 2 Trial ...
Jan 8, 2025 Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring …See details»
Anokion Announces Positive Symptom Data from its Phase 2 Trial ...
Jan 8, 2025 Cambridge, Mass. and Lausanne, Switzerland, January 8, 2025 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring …See details»
Anokion SA (Anokion SA) - 药物管线_专利_临床试验_投融营收_最 …
了解Anokion SA (Anokion SA)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 36篇新闻和2篇文献，疾病领域:免疫系统疾病，神经系统疾病，内分泌与代谢疾病，技术平 …See details»
SynCeD - Anokion
What is the SynCeD Study?. Phase 2A Study of KAN-101 Histologic Protection in Celiac Disease. We are investigating a potential treatment for Celiac Disease in a phase 2b clinical study. Are …See details»
ACeD-it Clinical Trial Study - Anokion
What is the ACeD-it Study?. Phase 1b/2 Assessment of KAN-101 in Celiac Disease and Immune Tolerance. We are investigating a potential treatment for Celiac Disease in a phase 1b/2 …See details»